IP Library Granted Patent US 7,052,913
Granted Patent B2
US 7,052,913 · App. 10/838,423 · Granted May 30, 2006

Matrices for drug delivery and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,052,913
App. No.
10/838,423
Granted
May 30, 2006
Kind
B2
Abstract

In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L -amino acid decarboxylase is encapsulated and implanted in the brain to convert L -dopa to dopamine for treatment of Parkinson's disease.

Claims (30)

1. A medical article comprising:

a. an inorganic-based sol-gel matrix that is biocompatible; and,

b. a first reaction center encapsulated in said matrix,

wherein upon placing said article comprising said biocompatible matrix in contact with tissue and/or fluids of a subject, said first reaction center converts a first prodrug into a first biologically active agent.

2. The medical article of claim 1 , wherein said first prodrug is endogenous to said subject and is more deleterious to said subject than said first biologically active agent.

3. The medical article of claim 1 , wherein said fluid is blood of said subject.

4. The medical article of claim 1 , wherein said article consists entirely of said biocompatible matrix.

5. The medical article of claim 2 , wherein said article is implantable.

6. The medical article of claim 4 , wherein said biocompatible matrix is attached to said article.

7. The medical article of claim 4 , wherein said biocompatible matrix is attached to said article as a thin film.

8. The medical article of claim 4 , wherein said biocompatible matrix is attached to said article in a capsule.

9. The medical article of claim 1 , wherein said biocompatible matrix is incorporated within said article.

10. The medical article of claim 1 , wherein said article is a tissue assist device, wherein said first reaction center provides a biological function characteristic of tissue of said subject.

11. The medical article of claim 10 , wherein said contact occurs extracorporeal to said subject.

12. The medical article of claim 10 , wherein said tissue of said subject is deficient in converting said first prodrug into said first biologically active agent.

13. A method for producing a medical article of claim 1 comprising:

a. encapsulating a first cell-free reaction center in a biocompatible matrix; and

b. shaping said matrix into a desired morphology;

wherein said biocompatible matrix comprises an inorganic-based sol-gel matrix and wherein said first reaction center converts a first prodrug into a first biologically active agent.

14. The method of claim 13 , wherein said matrix is cast into a morphology selected from one of the following: cylindrical, rectangular, disk-shaped, patch-shaped, ovoid, stellate, or spherical.

15. The method of claim 13 , wherein said matrix is cast or sprayed as a thin film onto said medical article.

16. The method of claim 13 , wherein said biocompatible matrix comprises a silica-based sol-gel matrix.

17. The method of claim 13 , wherein said biocompatible matrix is prepared from at least one type of oxysilane.

18. The method of claim 17 , wherein said biocompatible matrix is prepared from more than one type of oxysilane.

19. The method of claim 13 , wherein said biocompatible matrix is prepared from at least one type of inorganic oxide and at least one type of oxysilane.

20. A method for producing a medical article of claim 1 comprising:

a. encapsulating a first cell-free reaction center in a biocompatible matrix;

b. crushing said biocompatible matrix; and

c. encapsulating said crushed biocompatible matrix;

wherein said biocompatible matrix comprises an inorganic-based sol-gel matrix and wherein said first reaction center converts a first prodrug into a first biologically active agent.

Assignments (1)
RELEASE OF PATENT SECURITY INTEREST Recorded Jan 18, 2013
From: NEXBANK, SSB (AS COLLATERAL AGENT)
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 029660/0618 →